Combination product: mavrilimumab    (DrugBank: Mavrilimumab)

1 disease
IDDisease name (Link within this page)Number of trials
41Giant cell arteritis1

41. Giant cell arteritis    [ 108 clinical trials,   111 drugs,   (DrugBank: 32 drugs),   33 drug target genes,   121 drug target pathways]
Searched query = "Giant cell arteritis", "Temporal arteritis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 108 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT03827018
(ClinicalTrials.gov)
December 21, 201825/1/2019KPL-301 for Subjects With Giant Cell ArteritisA Phase 2, Randomized, Double-blind Placebo-controlled Study to Test the Efficacy and Safety of KPL-301 in Giant Cell ArteritisGiant Cell ArteritisCombination Product: mavrilimumab;Combination Product: placeboKiniksa Pharmaceuticals, Ltd.NULLActive, not recruiting50 Years85 YearsAll70Phase 2United States;Australia;Belgium;Croatia;Estonia;Germany;Ireland;Italy;Netherlands;New Zealand;Poland;Serbia;Slovenia;Spain;United Kingdom